Literature DB >> 23837797

LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor.

Jianyong Chen1, Cheng Jiang, Shaomeng Wang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23837797     DOI： 10.1021/jm401005u

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  14 in total

1.  PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Authors:  Helen Y Zou; Luc Friboulet; David P Kodack; Lars D Engstrom; Qiuhua Li; Melissa West; Ruth W Tang; Hui Wang; Konstantinos Tsaparikos; Jinwei Wang; Sergei Timofeevski; Ryohei Katayama; Dac M Dinh; Hieu Lam; Justine L Lam; Shinji Yamazaki; Wenyue Hu; Bhushankumar Patel; Divya Bezwada; Rosa L Frias; Eugene Lifshits; Sidra Mahmood; Justin F Gainor; Timothy Affolter; Patrick B Lappin; Hovhannes Gukasyan; Nathan Lee; Shibing Deng; Rakesh K Jain; Ted W Johnson; Alice T Shaw; Valeria R Fantin; Tod Smeal
Journal:  Cancer Cell       Date:  2015-07-02       Impact factor: 31.743

2.  Synthesis of a [(18)F]-labeled ceritinib analogue for positron emission tomography of anaplastic lymphoma kinase, a receptor tyrosine kinase, in lung cancer.

Authors:  Sandun Perera; David Piwnica-Worms; Mian M Alauddin
Journal:  J Labelled Comp Radiopharm       Date:  2016-02-08       Impact factor: 1.921

Review 3.  Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.

Authors:  Bryan A Chan; Brett G M Hughes
Journal:  Transl Lung Cancer Res       Date:  2015-02

Review 4.  ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.

Authors:  Mark M Awad; Alice T Shaw
Journal:  Clin Adv Hematol Oncol       Date:  2014-07

Review 5.  Anaplastic lymphoma kinase: Role in cancer and therapy perspective.

Authors:  Zhihong Zhao; Vivek Verma; Mutian Zhang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 6.  Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.

Authors:  Hideko Isozaki; Nagio Takigawa; Katsuyuki Kiura
Journal:  Cancers (Basel)       Date:  2015-04-30       Impact factor: 6.639

7.  Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors.

Authors:  Marica Peron; Federica Lovisa; Elena Poli; Giuseppe Basso; Paolo Bonvini
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

Review 8.  Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors.

Authors:  Puey Ling Chia; Paul Mitchell; Alexander Dobrovic; Thomas John
Journal:  Clin Epidemiol       Date:  2014-11-20       Impact factor: 4.790

Review 9.  Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.

Authors:  Mariacarmela Santarpia; Maria Grazia Daffinà; Alessandro D'Aveni; Grazia Marabello; Alessia Liguori; Elisa Giovannetti; Niki Karachaliou; Maria Gonzalez Cao; Rafael Rosell; Giuseppe Altavilla
Journal:  Drug Des Devel Ther       Date:  2017-07-05       Impact factor: 4.162

10.  ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.

Authors:  D N Debruyne; N Bhatnagar; B Sharma; W Luther; N F Moore; N-K Cheung; N S Gray; R E George
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.